Discover verified cancer discoveries

Search and filter stories that passed editorial review. Evidence strength, regulatory status, and guideline position are shown separately and are never inferred from one another.

Filter discoveries

Results

Active filters:Clear all

1 verified discovery matches your filters.

Lunresertib plus camonsertib produces durable responses in advanced endometrial and ovarian cancer in early trial data

Evidence stage: Emerging ClinicalRegulatory status: Investigational
Cancer type
Endometrial (Uterine) Cancer
Published
August 13, 2026

In the gynecologic expansion cohort of the first-in-human, phase 1 MYTHIC trial, the combination of lunresertib (a PKMYT1 inhibitor) and camonsertib (an ATR inhibitor) produced durable objective responses in heavily…

Primary source cited

Last reviewed